Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

Prothena said last week it had abandoned its lead product after a Phase 3 amyloidosis failure and is planning “substantial” layoffs. The company previously ditched the same drug, birtamimab, after a mid ...